Literature DB >> 2422464

The renal response to acute hypervolemia is caused by atrial natriuretic peptides.

C Hirth, J P Stasch, A John, S Kazda, F Morich, D Neuser, S Wohlfeil.   

Abstract

In anesthetized rats, synthetic rat atriopeptin II produced an increase in urinary volume and sodium excretion as well as a decrease in arterial blood pressure. Both the natriuretic and hypotensive effects were blocked by monoclonal antibodies directed against atriopeptin II. The diuresis and natriuresis caused by furosemide was not inhibited by these antibodies. Thus, the monoclonal antibodies provide a specific inhibitor for atriopeptin-mediated responses in vivo and can be used to investigate the role of atriopeptin in volume regulation. Volume expansion with 20 ml/kg i.v. homologous blood induced strong diuresis and natriuresis in the anaesthetized rat. This response was also blocked by the described monoclonal antibodies. A radioimmunoassay for the determination of atriopeptin-like immunoreactivity (ANP-IR) is described. The plasma levels of ANP-IR 8 min after blood injection were 3-4 times higher than in control rats. Thus, the strong diuresis observed after volume expansion is due to an increase in circulating atrial natriuretic peptides that obviously exert a regulative function in fluid volume control.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422464     DOI: 10.1097/00005344-198603000-00008

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  A comparison of head-down tilt with low-dose infusion of atrial natriuretic peptide in man.

Authors:  M J Allen; V T Ang; D Bennett
Journal:  J Physiol       Date:  1989-03       Impact factor: 5.182

2.  Is atriopeptin a physiological or pathophysiological substance? Studies in the autoimmune rat.

Authors:  J E Greenwald; M Sakata; M L Michener; S D Sides; P Needleman
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

3.  Paradoxical relationship between atriopeptin plasma levels and diuresis-natriuresis induced by acute volume expansion.

Authors:  M Sakata; J E Greenwald; P Needleman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

4.  Increase in plasma concentrations of cardiodilatin (amino terminal pro-atrial natriuretic peptide) in cardiac failure and during recumbency.

Authors:  L Meleagros; J S Gibbs; M A Ghatei; S R Bloom
Journal:  Br Heart J       Date:  1988-07

5.  Increased tubuloglomerular feed-back mediated suppression of glomerular filtration during acute volume expansion in rats.

Authors:  J M Davis; D A Häberle; T Kawata; E Schmitt; T Takabatake; S Wohlfeil
Journal:  J Physiol       Date:  1988-01       Impact factor: 5.182

6.  Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation.

Authors:  M R Wilkins; S L Settle; P Needleman
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

7.  Chronic blockade of endogenous atrial natriuretic polypeptide (ANP) by monoclonal antibody against ANP accelerates the development of hypertension in spontaneously hypertensive and deoxycorticosterone acetate-salt-hypertensive rats.

Authors:  H Itoh; K Nakao; M Mukoyama; T Yamada; K Hosoda; G Shirakami; N Morii; A Sugawara; Y Saito; S Shiono
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

8.  Plasma levels of atrial natriuretic peptide are raised in essential hypertension during low and high sodium intake.

Authors:  G Wambach; S Götz; G Suckau; G Bönner; W Kaufmann
Journal:  Klin Wochenschr       Date:  1987-03-02

9.  The use of a monoclonal antibody for the determination of atrial natriuretic peptides in human plasma.

Authors:  J P Stasch; D Neuser; A John; D Hein; K Heuck; F J Morich
Journal:  Klin Wochenschr       Date:  1987-07-15

10.  The syndrome of hypertension and hyperkalaemia with normal glomerular function (Gordon's syndrome). A pathophysiological study.

Authors:  B Semmekrot; L Monnens; B G Theelen; W Rascher; F Gabreëls; J Willems
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.